研究者
J-GLOBAL ID：201801021417723680   更新日: 2024年01月30日

田村 亮太

Ryota Tamura
研究分野 (1件)： その他
競争的資金等の研究課題 (2件)：
  • 2022 - 2025 神経線維腫症2型の微小低酸素環境の解明と新たな治療戦略の提言
  • 2016 - 2017 iPS細胞を用いた悪性グリオーマに対する遺伝子細胞治療の基礎的研究
論文 (55件)：
  • Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
  • Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Yohei Yamamoto, Ryotaro Imai, Yuki Kuranai, Kyoichi Tohmoto, Yuzuru Hasegawa, et al. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma. 2023
  • Ryota Tamura, Akio Iwanami, Kentaro Ohara, Masaaki Nishimoto, Eriel Sandika Pareira, Tomoru Miwa, Naoko Tsuzaki, Yuki Kuranari, Yukina Morimoto, Masahiro Toda, et al. Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence. Brain Tumor Pathology. 2023
  • Ryota Tamura, Akio Iwanami, Kentaro Ohara, Masaaki Nishimoto, Eriel Sandika Pareira, Tomoru Miwa, Naoko Tsuzaki, Yuki Kuranari, Yukina Morimoto, Masahiro Toda, et al. Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence. Brain Tumor Pathology. 2023
  • Ryota Tamura, Hiroki Oda, Kenzo Kosugi, Masahiro Toda. Surgical Planning and Simulation of Endonasal Endoscopic Surgery for Pituitary Adenoma With Cavernous Sinus Invasion. Operative neurosurgery (Hagerstown, Md.). 2022. 23. 4. e276-e282
もっと見る
MISC (7件)：
  • Tanaka T, Tamura R, Takei J, Morimoto Y, Teshigawara A, Tohmoto K, K, Kuranari Y, Imai R, Yamamoto Y, et al. A prospective multicenter phase I/IIa study of prospective neoadjuvant bevacizumab for newly diagnosed glioblastoma. Neuro-Oncology Advances. 2022. 4. 3. iii7
  • 田中俊英, 武井淳, 勅使川原明彦, 東本杏一, 山本洋平, 長谷川譲, 田村亮太, 佐々木光, 赤崎安晴, 村山雄一. 神経膠芽腫における腫瘍幹細胞,TAMの極性,酸素化に対するベバシズマブの効果. 日本脳腫瘍学会プログラム・抄録集. 2021. 3. 6. vi1
  • Ryota Tamura, Mizuto Sato, Yukina Morimoto, Kentaro Ohara, Kenzo Kosugi, Yumiko Oishi, Yuki Kuranari, Makoto Murase, Kazunari Yoshida, Masahiro Toda. Quantitative assessment and clinical relevance of VEGFRs-positive tumor cells in refractory brain tumors. Experimental and molecular pathology. 2020. 114. 104408-104408
  • Tanaka T, Tamura R, Yamamoto Y, Morimoto Y, Teshigawara A, Tochigi S, Hasegawa Y, Takei J, Sasaki H, Murayama Y. Alteration in immune regulatory cels before and after treatment by Stupp regimen with or without bevacizumab for glioblastoma. Neuro-Oncology Advances. 2019. 1. 2. ii4-iii5
  • Tomoru Miwa, Ryota Tamura, Tomo Horikoshi, Kazunari Yoshida. PURE AQUEDUCTAL PILOCYTIC ASTROCYTOMA. NEURO-ONCOLOGY. 2016. 18. 88-88
もっと見る
※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。 登録・更新については、こちらをご覧ください。

前のページに戻る

TOP

BOTTOM